Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

The enrollment for the KT-621 (STAT6) BROADEN2 Phase 2b AD trial has been finished nearly six months earlier than the expected timeline. Data from the trial is anticipated to be available by the end of 2026.